IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
The study will be a prospective, pragmatic, randomized clinical trial of the comparative effectiveness of an initial strategy for the treatment of uncomplicated type B aortic dissection (uTBAD). Patients with uTBAD and no prior history of aortic intervention will be randomized within 48 hours to 6 weeks after index admission to one of the two initial strategies. Follow-up will be ascertained via a centralized call center and ascertainment of medical records, as well as remote blood pressure monitoring. Recommendations regarding medical therapy will be made to enrolling centers and feedback on the quality of medical care given, however, all subsequent care, with the exception of aortic interventions, will be at the discretion of the responsible clinical care team. Aortic interventions will allowable only as per protocol.
Inclusion Criteria:
Exclusion Criteria:
megan.roebuck@duke.edu919-316-0628
kady.ann.steen.burrell@duke.edu919-530-9711
Birmingham, Alabama 35294, United States
480-323-1046
415-353-4368
860-972-1788
352-273-7598
813-844-4686
312-926-4000
217-545-7321
207-662-2090
617-726-8875
617-525-8555
508-856-1767
313-916-8006
612-624-7463
573-884-7569
856-342-2150
212-241-4461
585-276-1738
315-464-8272
216-844-2988
971-349-6659
412-647-8467
512-324-3434
214-648-6743
832-301-1168
832-301-1168
713-486-5194
801-587-1450
757-388-7511
304-388-9944
414-955-1810
514-890-8000 ext. 30988
514-718-5025